AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10803112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract (DY) with softstart-polymerization (SSP)
Number of subjects: 20
Study 10803112 — intervention group
Group type: EXPERIMENTAL
Intervention: Hytac (HY) with conventional polymerization (CP)
Number of subjects: 20
Study 10803112 — intervention group
Group type: EXPERIMENTAL
Intervention: Hytac (HY) with softstart-polymerization (SSP)
Number of subjects: 20
Study 10803112 — intervention group
Group type: EXPERIMENTAL
Intervention: Hytac (HY) with both polymerization modes without preparation
Number of subjects: 20
Study 10803112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract (DY) with softstart-polymerization (SSP) without preparation
Number of subjects: 20
Study 10803112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract (DY) and Hytac (HY) with preparation
Number of subjects: 20
Study 8771419 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallstents
Number of subjects: 87
Study 8771419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraflex stents
Number of subjects: 87
Study 8771419 — intervention group
Group type: EXPERIMENTAL
Intervention: Gianturco-Z stents
Number of subjects: 87
Study 8771419 — intervention group
Group type: EXPERIMENTAL
Intervention: All stent types
Number of subjects: 87
Study 1611832 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet
Number of subjects: 18
Study 1611832 — intervention group
Group type: COMPARATOR
Intervention: High glycaemic index diet
Number of subjects: 18
Study 6428513 — intervention group
Group type: EXPERIMENTAL
Intervention: Single channel cystometry
Number of subjects: 100
Study 6428513 — intervention group
Group type: COMPARATOR
Intervention: Multichannel cystometry
Number of subjects: 100
Study 31690794 — intervention group
Group type: EXPERIMENTAL
Intervention: OS-MRSA isolates
Number of subjects: 74
Study 31690794 — intervention group
Group type: COMPARATOR
Intervention: MRSA isolates
Number of subjects: 74
Study 31690794 — intervention group
Group type: EXPERIMENTAL
Intervention: All isolates
Number of subjects: 74
Study 31690794 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR isolates
Number of subjects: 74
Study 31690794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive isolates
Number of subjects: 74
Study 29250843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon powder capsules 1.5 g/day in 3 divided doses for 12 weeks
Number of subjects: 66
Study 29250843 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 66
Study 26054202 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment
Number of subjects: 200
Study 26054202 — intervention group
Group type: COMPARATOR
Intervention: Medication group (controlled ovarian hyperstimulation using Diane‐35, Decepepty, Gonadotrophin, human Chorionic Gonadotrophin)
Number of subjects: 200
Study 23587135 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS treatment (30 minutes simultaneous electrical stimulation of the posterior neck and the right Zusanli acupoint)
Number of subjects: 15
Study 23587135 — intervention group
Group type: COMPARATOR
Intervention: Simulator exposure (control condition)
Number of subjects: 15
Study 21399959 — intervention group
Group type: EXPERIMENTAL
Intervention: ST(BFR) - Blood flow restriction for stimulated thigh
Number of subjects: 7
Study 21399959 — intervention group
Group type: COMPARATOR
Intervention: NT(BFR) - Blood flow restriction for non-stimulated thigh
Number of subjects: 7
Study 21399959 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ST(BFR) and NT(BFR)
Number of subjects: 7
Study 19678948 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg t.i.d.
Number of subjects: 9
Study 19678948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 19678948 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-maintenance program
Number of subjects: 9
Study 17432402 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z250
Number of subjects: 38
Study 17432402 — intervention group
Group type: COMPARATOR
Intervention: CSE non‐etch
Number of subjects: 38
Study 17432402 — intervention group
Group type: COMPARATOR
Intervention: CSE etch
Number of subjects: 38
Study 17432402 — intervention group
Group type: EXPERIMENTAL
Intervention: Durafill VS (microfilled composite)
Number of subjects: 38
Study 17432402 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme (nanofilled composite)
Number of subjects: 38
Study 15175561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine capsules (2 x 10 mg doses given q8h for a total of three doses)
Number of subjects: 25
Study 15175561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine prolonged action tablets (20 mg doses given q12h for a total of two doses)
Number of subjects: 25
Study 15175561 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS tablet (60 mg single dose)
Number of subjects: 25
Study 11579872 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated curtains
Number of subjects: 0
Study 8470059 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 U/kg of AT-III concentrate (Group A)
Number of subjects: 8
Study 8470059 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U/kg of AT-III concentrate (Group B)
Number of subjects: 8
Study 8470059 — intervention group
Group type: COMPARATOR
Intervention: Heparin (small amounts detected in AT-III concentrates)
Number of subjects: 8
Study 3956940 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of cisapride
Number of subjects: 12
Study 3956940 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of cisapride
Number of subjects: 12
Study 3956940 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study 31281181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 31281181 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic Acid (FA)
Number of subjects: 175
Study 31281181 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine
Number of subjects: 175
Study 31281181 — intervention group
Group type: EXPERIMENTAL
Intervention: FA + L-thyroxine
Number of subjects: 175
Study 30260741 — intervention group
Group type: COMPARATOR
Intervention: Ozone therapy
Number of subjects: 36
Study 30260741 — intervention group
Group type: COMPARATOR
Intervention: Laser photobiomodulation
Number of subjects: 36
Study 30260741 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 27129871 — intervention group
Group type: EXPERIMENTAL
Intervention: MD+aPDT
Number of subjects: 67
Study 27129871 — intervention group
Group type: COMPARATOR
Intervention: MD only
Number of subjects: 67
Study 25006185 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular NSAID use
Number of subjects: 160801
Study 25006185 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective cox‐2 inhibitors (e.g., celecoxib)
Number of subjects: 160801
Study 25006185 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective agents with cox‐2>cox‐1 inhibition (e.g., naproxen)
Number of subjects: 160801
Study 25006185 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective agents with cox‐1>cox‐2 inhibition (e.g., ibuprofen)
Number of subjects: 160801
Study 23684823 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 331
Study 23684823 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 331
Study 23684823 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 plus PPV23
Number of subjects: 331
Study 23684823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 20442581 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 20442581 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 60
Study 20208198 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally customized program (Esperanza y Vida)
Number of subjects: 847
Study 20208198 — intervention group
Group type: COMPARATOR
Intervention: Diabetes education program (control)
Number of subjects: 847
Study 16319505 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment
Number of subjects: 165
Study 16319505 — intervention group
Group type: COMPARATOR
Intervention: No antiretroviral treatment
Number of subjects: 165
Study 16319505 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPD presence
Number of subjects: 165
Study 16319505 — intervention group
Group type: COMPARATOR
Intervention: ASPD absence
Number of subjects: 165
Study 14614414 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-block appliance treatment
Number of subjects: 174
Study 14614414 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 174
Study 10910424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 32
Study 10910424 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 32
Study 8807727 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 103
Study 1461782 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine containing the strains Edmonston‐Zagreb, Rubini and Wistar Ra 27/3
Number of subjects: 201
Study 1461782 — intervention group
Group type: COMPARATOR
Intervention: Other types of trivalent measles-mumps-rubella vaccines (not specified)
Number of subjects: 201
Study 3528718 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative human albumin administration
Number of subjects: 161
Study 3528718 — intervention group
Group type: COMPARATOR
Intervention: Control group (no human albumin therapy)
Number of subjects: 161
Study 29266169 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 256
Study 29266169 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 256
Study 29266169 — intervention group
Group type: COMPARATOR
Intervention: Curettage vs. Expectant management
Number of subjects: 256
Study 27633174 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus casei Shirota)
Number of subjects: 417
Study 27633174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 24107227 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-review group intervention
Number of subjects: 0
Study 21733490 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 1200 mg/d
Number of subjects: 131
Study 21733490 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine 800 mg/d
Number of subjects: 131
Study 21921224 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir combined with tenofovir/emtricitabine
Number of subjects: 563
Study 21921224 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz combined with tenofovir/emtricitabine
Number of subjects: 563
Study 21921224 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 563
Study 21921224 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 563
Study 19836301 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital CMV infection
Number of subjects: 192
Study 19836301 — intervention group
Group type: COMPARATOR
Intervention: Newborn hearing screening (NHS)
Number of subjects: 192
Study 17047934 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 48
Study 17047934 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 48
Study 17047934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15257749 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CHX pre-brushing rinse with SLS-containing dentifrice (Colgate Total)
Number of subjects: 35
Study 15257749 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CHX pre-brushing rinse with SLS-containing dentifrice (Aquafresh Natural Whitening)
Number of subjects: 35
Study 15257749 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CHX pre-brushing rinse with SLS-free dentifrice (Zendium)
Number of subjects: 35
Study 15257749 — intervention group
Group type: COMPARATOR
Intervention: 0.2% CHX rinse only (control)
Number of subjects: 35
Study 10717506 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril
Number of subjects: 0
Study 10717506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10717506 — intervention group
Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 0
Study 9350607 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (5 mg/kg/day bid)
Number of subjects: 55
Study 9350607 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin (5 mg/kg/day once daily)
Number of subjects: 55
Study 8462498 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal attribution message
Number of subjects: 197
Study 8462498 — intervention group
Group type: COMPARATOR
Intervention: External attribution message
Number of subjects: 197
Study 8462498 — intervention group
Group type: COMPARATOR
Intervention: Information-only message
Number of subjects: 197
Study 3929659 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic hypoxia (8% O2 in N2)
Number of subjects: 15
Study 3929659 — intervention group
Group type: COMPARATOR
Intervention: Eucapnic hyperpnea with dry air
Number of subjects: 15
Study 29125700 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation C (2 × 25 mg)
Number of subjects: 58
Study 29125700 — intervention group
Group type: COMPARATOR
Intervention: Formulation D (2 × 12.5 mg)
Number of subjects: 58
Study 29125700 — intervention group
Group type: COMPARATOR
Intervention: Formulation E (2 × 12.5 mg)
Number of subjects: 58
Study 29125700 — intervention group
Group type: COMPARATOR
Intervention: Formulation C (1 × 25 mg) under fed conditions
Number of subjects: 58
Study 29125700 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 58
Study 27137422 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy for antepartum depression (IPT-P)
Number of subjects: 75
Study 27137422 — intervention group
Group type: COMPARATOR
Intervention: Parenting education program (PEP)
Number of subjects: 75
Study 25525278 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation and systematic desensitization
Number of subjects: 42
Study 25525278 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 42
Study 22305026 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 oz of cranberry juice daily
Number of subjects: 176
Study 22305026 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 oz of cranberry juice daily
Number of subjects: 176
Study 22305026 — intervention group
Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 176
Study 22305026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 176
Study 22305026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 20032170 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (at least weekly measurements)
Number of subjects: 0
Study 20032170 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 18655841 — intervention group
Group type: COMPARATOR
Intervention: FFIS 20microg
Number of subjects: 60
Study 18655841 — intervention group
Group type: EXPERIMENTAL
Intervention: FFIS 244microg
Number of subjects: 60
Study 18655841 — intervention group
Group type: COMPARATOR
Intervention: FFIS 10, 20, 244microg
Number of subjects: 60
Study 15797175 — intervention group
Group type: EXPERIMENTAL
Intervention: ANAM tasks measuring working memory
Number of subjects: 16
Study 15797175 — intervention group
Group type: EXPERIMENTAL
Intervention: ANAM efficiency scores
Number of subjects: 16
Study 15797175 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminant function analysis
Number of subjects: 16
Study 15797175 — intervention group
Group type: EXPERIMENTAL
Intervention: ANAM
Number of subjects: 16
Study 15797175 — intervention group
Group type: COMPARATOR
Intervention: MMSE scores
Number of subjects: 16
Study 12622932 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (50 micro g) plus recombinant hepatitis B vaccine (10 micro g) injected intramuscularly at the same location
Number of subjects: 27
Study 12622932 — intervention group
Group type: COMPARATOR
Intervention: HBIG (200 IU) plus recombinant hepatitis B vaccine (10 micro g) in different muscles
Number of subjects: 27
Study 10517191 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta antigen gene presence in GBS strains
Number of subjects: 163
Study 10517191 — intervention group
Group type: EXPERIMENTAL
Intervention: C protein beta antigen gene PCR analysis
Number of subjects: 163
Study 10517191 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine based on peptide antigens from beta antigen of C protein
Number of subjects: 163
Study 7497555 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with 1:200,000 epinephrine peritonsillar infiltration
Number of subjects: 43
Study 7497555 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% with 1:200,000 epinephrine spray
Number of subjects: 43
Study 7497555 — intervention group
Group type: COMPARATOR
Intervention: Normal saline spray (placebo)
Number of subjects: 43
Study 1645642 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-rank test
Number of subjects: 0
Study 1645642 — intervention group
Group type: EXPERIMENTAL
Intervention: Gehan's generalization of the Wilcoxon test
Number of subjects: 0
Study 1645642 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Kolmogorov-Smirnov test
Number of subjects: 0
Study 1645642 — intervention group
Group type: EXPERIMENTAL
Intervention: VA Cooperative Study No. 90
Number of subjects: 0
Study 6124803 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 15
Study 6124803 — intervention group
Group type: COMPARATOR
Intervention: Apomorphine (0.005 mg/kg)
Number of subjects: 15
Study 31725748 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle depth measurement on ultrasound (bicep, forearm, thigh)
Number of subjects: 78
Study 31725748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen balance measurement (g/24h)
Number of subjects: 78
Study 31725748 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum C-reactive protein, urinary urea, 3-methylhistidine measurements
Number of subjects: 78
Study 28608305 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiochemotherapy
Number of subjects: 0
Study 28608305 — intervention group
Group type: COMPARATOR
Intervention: Direct explorative laparotomy
Number of subjects: 0
Study 25331262 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus salivarius UBL S22
Number of subjects: 45
Study 25331262 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (Probiotic Lactobacillus salivarius UBL S22 + Prebiotic Fructo-oligosaccharide)
Number of subjects: 45
Study 25331262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 24122871 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant 100 mg
Number of subjects: 0
Study 24122871 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant 300 mg
Number of subjects: 0
Study 24122871 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant 450 mg
Number of subjects: 0
Study 24122871 — intervention group
Group type: EXPERIMENTAL
Intervention: [(14) C]‐netupitant 300 mg (ADME study)
Number of subjects: 0
Study 22526050 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery
Number of subjects: 70
Study 22526050 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 70
Study 19766760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (240 ml/day)
Number of subjects: 289
Study 19766760 — intervention group
Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 289
Study 17076064 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy model
Number of subjects: 0
Study 17076064 — intervention group
Group type: COMPARATOR
Intervention: Feature model
Number of subjects: 0
Study 15346227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance settings for LW males: 58.9, 63.8, 68.7, 73.7, 78.6 N; Peak 5 s PO RLF: 0.109 kg.kg(-1) BM; Mean 30 s PO RLF: 0.102 kg.kg(-1) BM.
Number of subjects: 31
Study 15346227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance settings for HW males: 83.5, 88.4, 93.4, 98.2, 103.1 N; Peak 5 s PO RLF: 0.102 kg.kg(-1) BM; Mean 30 s PO RLF: 0.095 kg.kg(-1) BM.
Number of subjects: 31
Study 15346227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance settings for LW females: 29.4, 34.3, 39.2, 44.1, 49.1 N; Peak 5 s PO RLF: 0.111 kg.kg(-1) BM; Mean 30 s PO RLF: 0.103 kg.kg(-1) BM.
Number of subjects: 31
Study 15346227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance settings for HW females: 44.1, 49.1, 54.0, 58.6, 63.8 N; Peak 5 s PO RLF: 0.076 kg.kg(-1) BM; Mean 30 s PO RLF: 0.068 kg.kg(-1) BM.
Number of subjects: 31
Study 15346227 — intervention group
Group type: COMPARATOR
Intervention: Concept II rowing machine; Peak 5 s PO significantly lower compared to the modified Gjessing rowing ergometer; Mean 30 s PO not significantly different.
Number of subjects: 31
Study 11273914 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluven
Number of subjects: 100
Study 11273914 — intervention group
Group type: COMPARATOR
Intervention: HAES‐steril
Number of subjects: 100
Study 9471921 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic exposure to carbon disulphide (CS2) at concentrations of 9.36‐23.4 mg/m3
Number of subjects: 199
Study 9471921 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic exposure to carbon disulphide (CS2)
Number of subjects: 199
Study 9471921 — intervention group
Group type: COMPARATOR
Intervention: Normal population (control group)
Number of subjects: 199
Study 8216014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide (2%)
Number of subjects: 48
Study 8216014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3315594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anisoylated plasminogen streptokinase activator complex (APSAC) 30U
Number of subjects: 82
Study 3315594 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5000U
Number of subjects: 82
Study 29859180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic strength training 3 times per week for 6 weeks
Number of subjects: 30
Study 29859180 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 30